Therapeutics News

Studies are beginning to demonstrate that cannabidiol may hold potential for treating various skin conditions, yet clinicians should use caution, as the products remain unregulated by the FDA and robust clinical data are lacking, according to findings published in Clinics in Dermatology.

Complementary and alternative medicines in psoriasis are typically employed by patients for who traditional treatment regimens are unsuccessful, and few report limited care access as a reason for seeking out alternative therapies, according to survey results published in the Journal of the American Academy of Dermatology.

In a cross-sectional analysis of price increases in topical medications, among generics, antineoplastics, retinoids and topical corticosteroids had the most increases since 2014, based on National Average Drug Acquisition Cost data from the Medicaid Pharmacy Pricing database from 2014 to 2018.

Patients with rosacea treated with topical ivermectin 1% cream and oral doxycycline modified-release 40 mg capsules had greater visible improvement and decreased stinging and flushing compared with monotherapy, according to data from a multicenter, randomized, parallel-group comparison study conducted by James Q. Del Rosso, DO, of JDR Dermatology Research/Thomas Dermatology in Las Vegas, and colleagues.

Inflammation plays a key role in male and female pattern hair loss, Neal Walker, DO, president and CEO of Aclaris Therapeutics, said in an interview with Healio Dermatology regarding results from a phase 2 open-label clinical trial in subjects with androgenetic alopecia.

Patients with moderatetosevere psoriasis treated with ixekizumab showed high rates of improvement and no unexpected safety outcomes for up to 5 years of treatment, according to study results presented at World Congress of Dermatology in Milan.

Patients with central obesity, insulin resistance and active psoriasis are at high risk for liver fibrosis, according to researchers from King’s College London.

Most patients with moderate to severe plaque psoriasis who received treatment with brodalumab experienced long-term rates of skin clearance at 120 weeks, according to extension results of AMAGINE-2.

IFX-1, a monoclonal anti-human complement factor C5a antibody, showed no significant dose response in patients with hidradenitis suppurativa at week 16 of the SHINE phase 2b study.

Topical calcineurin inhibitors may produce a favorable response in patients with vitiligo, with monotherapy appearing to be effective in children and in those with lesions on the face and neck.